通过收购Handl Therapeutics公司，优时比将获得两个在研项目。

Lacerta Therapeutics将主导研究、临床前活动和早期生产工艺开发，而优时比将完成IND授权研究、生产和临床开发。这项新的合作将使优时比能够获得Lacerta Therapeutics在基于AAV的CNS靶向基因治疗方面的专业知识，强化优时比有效治疗神经退行性疾病的能力。

参考资料：

[1] UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms. Retrieved November 12, 2020, from https://www.ucb.com/stories-media/Press-Releases/article/UCB-strengthens-its-gene-therapy-activities-with-additional-pipeline-programs-capabilities-and-platforms